Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis

  1. Sina C Rosenkranz
  2. Artem A Shaposhnykov
  3. Simone Träger
  4. Jan Broder Engler
  5. Maarten E Witte
  6. Vanessa Roth
  7. Vanessa Vieira
  8. Nanne Paauw
  9. Simone Bauer
  10. Celina Schwencke-Westphal
  11. Charlotte Schubert
  12. Lukas Can Bal
  13. Benjamin Schattling
  14. Ole Pless
  15. Jack van Horssen
  16. Marc Freichel
  17. Manuel A Friese  Is a corresponding author
  1. University Medical Centre Hamburg-Eppendorf, Germany
  2. University Medical Centre Hamburg-Eppendorf Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Germany
  3. Amsterdam UMC, Netherlands
  4. Fraunhofer IME, Germany
  5. University of Heidelberg, Germany

Abstract

While transcripts of neuronal mitochondrial genes are strongly suppressed in central nervous system inflammation, it is unknown whether this results in mitochondrial dysfunction and whether an increase of mitochondrial function can rescue neurodegeneration. Here we show that predominantly genes of the electron transport chain are suppressed in inflamed mouse neurons resulting in impaired mitochondrial complex IV activity. This was associated with posttranslational inactivation of the transcriptional co-regulator PGC-1α. In mice, neuronal overexpression of Ppargc1a, which encodes for PGC-1α, led to increased numbers of mitochondria, complex IV activity and maximum respiratory capacity. Moreover, Ppargc1a overexpressing neurons showed a higher mitochondrial membrane potential that related to an improved calcium buffering capacity. Accordingly, neuronal deletion of Ppargc1a aggravated neurodegeneration during experimental autoimmune encephalomyelitis (EAE), while neuronal overexpression of Ppargc1a ameliorated it. Our study provides systemic insights into mitochondrial dysfunction in neurons during inflammation and commends elevation of mitochondrial activity as a promising neuroprotective strategy.

Data availability

All current data have been provided. Supplemental figures are included in the article file. All individual data are reported within the figure graphs as scatter plots. Numerical data for Figure 3E, 5A and 5C can be found as Source Data.Enrichment analysis was performed using the function 'gseGO' of the R package clusterProfiler; plotting was performed with the R packages ggplot2, clusterProfiler and tidyheatmap.Normalization, calcium spikes, base line detection, and analysis of the calcium clearance rate were performed with the custom-made script written on Python 3.6 (https://github.com/scriptcalcium/PGC1alpha).

The following previously published data sets were used

Article and author information

Author details

  1. Sina C Rosenkranz

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Artem A Shaposhnykov

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Simone Träger

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Jan Broder Engler

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Maarten E Witte

    Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Vanessa Roth

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Vanessa Vieira

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Nanne Paauw

    Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  9. Simone Bauer

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Celina Schwencke-Westphal

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Charlotte Schubert

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Lukas Can Bal

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Benjamin Schattling

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8809-9073
  14. Ole Pless

    ScreeningPort, Fraunhofer IME, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1468-316X
  15. Jack van Horssen

    Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  16. Marc Freichel

    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1387-2636
  17. Manuel A Friese

    Institute of Neuroimmunology and Multiple Sclerosis (INIMS), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
    For correspondence
    manuel.friese@zmnh.uni-hamburg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6380-2420

Funding

Stifterverband (Clinician-Scientist Fellowship)

  • Sina C Rosenkranz

Gemeinnützige Hertie-Stiftung (Hertie Network of Excellence in Clinical Neuroscience)

  • Sina C Rosenkranz

Deutsche Forschungsgemeinschaft (FR1720/9-1,FR1720/9-2)

  • Manuel A Friese

Deutsche Forschungsgemeinschaft (FR1638/3-1,FR1638/3-2)

  • Marc Freichel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal care and experimental procedures were performed according to institutional guidelines and conformed to requirements of the German Animal Welfare Act. All animal experiments were approved by the local ethics committee (Behörde für Soziales, Familie, Gesundheit und Verbraucherschutz in Hamburg; G22/13 and 122/17). We conducted all procedures in accordance with the ARRIVE guidelines (Kilkenny et al., 2010).

Copyright

© 2021, Rosenkranz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,695
    views
  • 591
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sina C Rosenkranz
  2. Artem A Shaposhnykov
  3. Simone Träger
  4. Jan Broder Engler
  5. Maarten E Witte
  6. Vanessa Roth
  7. Vanessa Vieira
  8. Nanne Paauw
  9. Simone Bauer
  10. Celina Schwencke-Westphal
  11. Charlotte Schubert
  12. Lukas Can Bal
  13. Benjamin Schattling
  14. Ole Pless
  15. Jack van Horssen
  16. Marc Freichel
  17. Manuel A Friese
(2021)
Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis
eLife 10:e61798.
https://doi.org/10.7554/eLife.61798

Share this article

https://doi.org/10.7554/eLife.61798

Further reading

    1. Immunology and Inflammation
    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.